Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IDO Emerges As Clean Combo Partner, Rising Star At AACR

Executive Summary

Clean safety profile for combination of IDO inhibitors with anti-PD-1 agents in early studies presented at the American Association for Cancer Research meeting contrasts with the toxicity-laden CTLA-4/PD-1 regimen in Bristol's Phase III CheckMate 067 study.

Advertisement

Related Content

Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well
It's Not All About IO: Seven Drugs To Watch At ASCO
Scrip's Rough Guide To IDO
Bristol's CheckMate 067 Revives Debate On Rationing Yervoy/Opdivo Combo
Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration
Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing
J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More
Can Checkpoint Inhibitors Jump-Start Glioblastoma Drug Development?
Flexus flips IDO inhibitors to Bristol-Myers for up to $1.25bn
ASCO Immunotherapy Alert: BioMedTracker’s Top Abstract Picks

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098512

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel